The DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases
Open accessAbstract
Importance: Recent genome-wide association studies (GWAS) and pathway analyses supported long-standing observations of an association between immune-mediated diseases and Parkinson disease (PD). The post-GWAS era provides an opportunity for cross-phenotype analyses between different complex phenotypes. Objectives: To test the hypothesis that there are common genetic risk variants conveying risk of both PD and autoimmune diseases (ie, pleiotropy) and to identify new shared genetic variants and their pathways by applying a novel statistical framework in a genome-wide approach. Design, Setting, and Participants: Using the conjunction false discovery rate method, this study analyzed GWAS data from a selection of archetypal autoimmune diseases among 138 511 individuals of European ancestry and systemically investigated pleiotropy between PD and type 1 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease, psoriasis, and multiple sclerosis. NeuroX data (6927 PD cases and 6108 controls) were used for replication. The study investigated the biological correlation between the top loci through protein-protein interaction and changes in the gene expression and methylation levels. The dates of the analysis were June 10, 2015, to March 4, 2017. Main Outcomes and Measures: The primary outcome was a list of novel loci and their pathways involved in PD and autoimmune diseases. Results: Genome-wide conjunctional analysis identified 17 novel loci at false discovery rate less than 0.05 with overlap between PD and autoimmune diseases, including known PD loci adjacent to GAK, HLA-DRB5, LRRK2, and MAPT for rheumatoid arthritis, ulcerative colitis and Crohn disease. Replication confirmed the involvement of HLA, LRRK2, MAPT, TRIM10, and SETD1A in PD. Among the novel genes discovered, WNT3, KANSL1, CRHR1, BOLA2, and GUCY1A3 are within a protein-protein interaction network with known PD genes. A subset of novel loci was significantly associated with changes in methylation or expression levels of adjacent genes. Conclusions and Relevance: The study findings provide novel mechanistic insights into PD and autoimmune diseases and identify a common genetic pathway between these phenotypes. The results may have implications for future therapeutic trials involving anti-inflammatory agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Multiple common genetic variants between PD patients and other inflammatory diseases have been identified.249,250”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [249]
The cited source says what the claim attributes to it.
In the citing paper
“Genomewide association studies have alluded to a significant genetic overlap between Parkinson's disease and autoimmune diseases.97”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A. A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M. J., Lincoln, S., Kachergus, J. M., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,087
Self-citationGenome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593
Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., Lees, C. W., Balschun, T., Lee, J., Roberts, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.717 · Cited by 2,520
Self-citationInternational Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
Self-citation
Research works printed but not linked: 1
- [16]16. Nielsen NM, Pasternak B, Stenager E, Koch-Henriksen N, Frisch M. Multiple sclerosis and risk of Parkinson's disease: a Danish nationwide cohort study. Eur J Neurol. 2014;21(1):107-111. Medline:24053187
Cited by
Sorted by citations
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“Multiple common genetic variants between PD patients and other inflammatory diseases have been identified.(249,250) In addition, GWAS have identified several immune-related gene variants in PD,(251) including leucine rich repeat kinase 2 (LRRK2), glucosylceramidase (GBA), parkin RBR E3 ubiquitin protein ligase (PRKN)…”
BackgroundInflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Parkinson disease and the immune system - Associations, mechanisms and therapeutics
Tan, E.-K., Chao, Y.-X., West, A., Chan, L.-L., Poewe, W., & Jankovic, J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0344-4 · Cited by 457
Ülgen, E., Özışık, O., & Sezerman, O. U. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00858 · Cited by 471
Microglia and astrocyte dysfunction in parkinson's disease
Kam, T., Hinkle, J. T., Dawson, T. M., & Dawson, V. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105028 · Cited by 420
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Tan, A. H., Lim, S. Y., & Lang, A. E. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00681-2 · Cited by 392
Peter, I., Dubinsky, M., Bressman, S., Park, A., Lu, C., Chen, N., & Wang, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0605 · Cited by 386
Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities
Schmidt, M. F., Gan, Z. Y., Komander, D., & Dewson, G. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00706-7 · Cited by 379
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D. P., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 384
Villumsen, M., Aznar, S., Pakkenberg, B., Jess, T., & Brudek, T. (2018) · Gut · doi:10.1136/gutjnl-2017-315666 · Cited by 325
Yang, C., Farias, F. H. G., Ibanez, L., Suhy, A., Sadler, B., Fernandez, M. V., Wang, F., Bradley, J. L., Eiffert, B., Bahena, J. A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00886-6 · Cited by 290
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease
Galiano-Landeira, J., Torra, A., Vila, M., & Bové, J. (2020) · Brain · doi:10.1093/brain/awaa269 · Cited by 267
Discovery of shared genomic loci using the conditional false discovery rate approach
Smeland, O. B., Frei, O., Shadrin, A. A., O’Connell, K. S., Fan, C. C., Bahrami, S., Holland, D., Djurovic, S., Thompson, W. K., Dale, A. M., et al. (2019) · Human Genetics · doi:10.1007/s00439-019-02060-2 · Cited by 261
Self-citationThe Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease
Cheong, J. L. Y., Pablo‐Fernández, E. D., Foltynie, T., & Noyce, A. J. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191900 · Cited by 241
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 212
Neuroinflammation and Parkinson’s Disease—From Neurodegeneration to Therapeutic Opportunities
Araújo, B., Caridade-Silva, R., Soares-Guedes, C., Martins‐Macedo, J., Gomes, E. D., Monteiro, S., & Teixeira, F. G. (2022) · Cells · doi:10.3390/cells11182908 · Cited by 209
Immune system responses in Parkinson's disease: Early and dynamic
Tansey, M. G., & Romero‐Ramos, M. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14290 · Cited by 193
Hughes, C. D., Choi, M. L., Ryten, M., Hopkins, L., Drews, A., Botía, J. A., Iljina, M., Rodrigues, M., Gagliano, S. A., Gandhi, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1907-y · Cited by 177
LRRK2 regulation of immune-pathways and inflammatory disease
Wallings, R. L., & Tansey, M. G. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180463 · Cited by 181
Innate immune activation in neurodegenerative diseases
Castro‐Gomez, S., & Heneka, M. T. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.010 · Cited by 176
LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same
Berwick, D. C., Heaton, G. R., Azeggagh, S., & Harvey, K. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0344-2 · Cited by 181
NADPH oxidases in Parkinson’s disease: a systematic review
Bélarbi, K., Cuvelier, E., Destée, A., Gressier, B., & Chartier‐Harlin, M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0225-5 · Cited by 161
Boyd, R. J., Avramopoulos, D., Jantzie, L. L., & McCallion, A. S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02584-x · Cited by 168
Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links
Lee, H.-S., Lobbestael, E., Vermeire, S., Sabino, J., & Cleynen, I. (2021) · Gut · doi:10.1136/gutjnl-2020-322429 · Cited by 151
The immune system in Parkinson's disease: what we know so far
Roodveldt, C., Bernardino, L. I., Çakmak, Ö. Ö., Dragić, M., Fladmark, K. E., Ertan, S., Aktaş, B., Pita, C., Ciglar, L., Garraux, G., et al. (2024) · Brain · doi:10.1093/brain/awae177 · Cited by 151
Inflammatory bowel diseases and Parkinson's disease
Brudek, T. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191729 · Cited by 139
The risk of Parkinson’s disease in inflammatory bowel disease: A systematic review and meta-analysis
Zhu, F., Li, C., Gong, J., Zhu, W., Gu, L., & Li, N. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.09.017 · Cited by 136
The Gut-Brain Axis in Inflammatory Bowel Disease—Current and Future Perspectives
Günther, C., Rothhammer, V., Karow, M., Neurath, M., & Winner, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168870 · Cited by 123
Roles of Autophagy-Related Genes in the Pathogenesis of Inflammatory Bowel Disease
Kim, S., Eun, H. S., & Jo, E. (2019) · Cells · doi:10.3390/cells8010077 · Cited by 128
Kim, K. S., Marcogliese, P. C., Yang, J., Callaghan, S. M., Resende, V., Abdel-Messih, E., Marras, C., Visanji, N. P., Huang, J., Schlossmacher, M. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718946115 · Cited by 111
Mechanisms of PINK1, ubiquitin and Parkin interactions in mitochondrial quality control and beyond
Bayne, A. N., & Trempe, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03203-4 · Cited by 121
The Search for Environmental Causes of Parkinson’s Disease: Moving Forward
Chen, H., & Ritz, B. R. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181493 · Cited by 113
Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries
Camacho‐Soto, A., Gross, A., Nielsen, S. S., Dey, N., & Racette, B. A. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.02.008 · Cited by 102
Smeland, O. B., Shadrin, A. A., Bahrami, S., Broce, I., Tesli, M., Frei, O., Wirgenes, K. V., O’Connell, K. S., Krull, F., Bettella, F., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.026 · Cited by 98
Self-citationPark, S., Kim, J., Chun, J., Han, K., Soh, H., Kang, E. A., Lee, H. J., Im, J. P., & Kim, J. S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081191 · Cited by 99
Hughes, C. D., Choi, M. L., Ryten, M., Hopkins, L., Drews, A., Botía, J. A., Iljina, M., Rodrigues, M., Taliun, S. A. G., Gandhi, S., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1919-7 · Cited by 99
Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing
Labandeira, C. M., Bau, A. F., Ron, D. A., Álvarez, E., Alba, P. V., Garma, J. L., & Rodriguez-Perez, A. I. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.332122 · Cited by 96
Biological and Clinical Implications of Comorbidities in Parkinson’s Disease
Santiago, J. A., Bottero, V., & Potashkin, J. A. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00394 · Cited by 98
Zhu, Y., Yuan, M., Zhu, Y., Yang, F., Chen, W., Xu, Z.-Z., Xiang, Z.-B., & Xu, R.-S. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.317981 · Cited by 95
Videira, P. A., & Castro‐Caldas, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00381 · Cited by 94
Savitt, D., & Jankovic, J. J. (2019) · Drugs · doi:10.1007/s40265-019-01104-1 · Cited by 93
Lee, H., Flynn, R., Sharma, I., Haberman, E. R., Carling, P. J., Nicholls, F. J., Stegmann, M., Vowles, J., Haenseler, W., Wade‐Martins, R., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.04.001 · Cited by 80
The role of T cells in the pathogenesis of Parkinson’s disease
Chen, Z., Chen, S., & Liu, J. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.08.002 · Cited by 81
The Emerging Immunogenetic Architecture of Schizophrenia
Pouget, J. G. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby038 · Cited by 77
LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson’s
Wallings, R. L., Herrick, M. K., & Tansey, M. G. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00443 · Cited by 80
Intestinal Inflammation and Parkinson’s Disease
Li, Y., Chen, Y., Jiang, L., Zhang, J., Tong, X., Chen, D., & Le, W. (2021) · Aging and Disease · doi:10.14336/ad.2021.0418 · Cited by 75
Chen, S., & Lin, C. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00839-6 · Cited by 85
Shared genetic etiology underlying Alzheimer’s disease and major depressive disorder
Lutz, M. W., Sprague, D., Barrera, J., & Chiba‐Falek, O. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0769-y · Cited by 72
The roles and functions of Paneth cells in Crohn’s disease: A critical review
Yang, E., & Shen, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12958 · Cited by 77
Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease
Zimmermann, M., & Brockmann, K. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223277 · Cited by 76
Süß, P., Rothe, T., Hoffmann, A., Schlachetzki, J. C. M., & Winkler, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612104 · Cited by 72
Associations Between Diabetes Mellitus and Neurodegenerative Diseases
Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020542 · Cited by 80
Neuroinflammation in Parkinson’s Disease: Triggers, Mechanisms, and Immunotherapies
Wang, T., Shi, C., Luo, H., Zheng, H., Fan, L., Tang, M., Su, Y., Yang, J., Mao, C., & Xu, Y. (2021) · The Neuroscientist · doi:10.1177/1073858421991066 · Cited by 69
Profiling variable-number tandem repeat variation across populations using repeat-pangenome graphs
Lu, T.-Y. T., Munson, K. M., Lewis, A. P., Zhu, Q., Tallon, L. J., Devine, S. E., Lee, C., Eichler, E. E., & Chaisson, M. (2021) · Nature Communications · doi:10.1038/s41467-021-24378-0 · Cited by 60
Ruiz-Pozo, V. A., Tamayo-Trujillo, R., Cadena-Ullauri, S., Frias-Toral, E., Guevara-Ramírez, P., Paz-Cruz, E., Chapela, S., Montalván, M., Morales-López, T., Simancas-Racines, D., et al. (2023) · Nutrients · doi:10.3390/nu15163585 · Cited by 63
The systemic immune response in Parkinson’s disease: focus on the peripheral immune component
Lauritsen, J., & Romero‐Ramos, M. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.005 · Cited by 66
Immune mechanisms and shared immune targets in neurodegenerative diseases
Weiner, H. L. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01046-7 · Cited by 72
Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease
Wang, Z., Gao, G., Duan, C., & Yang, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108843 · Cited by 62
Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson’s Disease
König, A., Miranda, H. V., & Outeiro, T. F. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-171285 · Cited by 59
Thi Lai, T., Kim, Y. E., Nguyen, L. T. N., Thi Nguyen, T., Kwak, I. H., Richter, F., Kim, Y. J., & Ma, H.-I. (2024) · npj Parkinson's Disease · doi:10.1038/s41531-024-00640-2 · Cited by 56
Houser, M. C., Caudle, W. M., Chang, J., Kannarkat, G. T., Yang, Y., Kelly, S. D., Oliver, D. L., Joers, V. L., Shannon, K. M., Keshavarzian, A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01240-4 · Cited by 54
PARK7/DJ-1 promotes pyruvate dehydrogenase activity and maintains Treg homeostasis during ageing
Danileviciute, E., Zeng, N., Capelle, C., Paczia, N., Gillespie, M. A. K., Kurniawan, H., Benzarti, M., Merz, M. P., Coowar, D., Fritah, S., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00576-y · Cited by 56
O’Connell, K. S., Shadrin, A. A., Bahrami, S., Smeland, O. B., Bettella, F., Frei, O., Krull, F., Askeland, R. B., Walters, G. B., Davíðsdóttir, K., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0613-z · Cited by 60
Self-citationModeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases
Balestri, W., Sharma, R., da Silva, V. A., Bobotis, B. C., Curle, A. J., Kothakota, V., Kalantarnia, F., Hangad, M. V., Hoorfar, M., Jones, J., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03024-8 · Cited by 55
The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?
Jiang, T., Li, G., Xu, J., Gao, S., & Xu, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02047 · Cited by 53
Polygenic risk and pleiotropy in neurodegenerative diseases
Bellou, E., Stevenson‐Hoare, J. O., & Escott‐Price, V. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104953 · Cited by 59
Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases
Li, C. Y., Yang, T. M., Ou, R. W., Wei, Q. Q., & Shang, H. F. (2021) · BMC Medicine · doi:10.1186/s12916-021-01903-y · Cited by 48
Müller-Nedebock, A. C., Dekker, M. C. J., Farrer, M. J., Hattori, N., Lim, S., Mellick, G. D., Rektorová, I., Salama, M., Schuh, A. F. S., Stoessl, A. J., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00535-8 · Cited by 49
Pathogenesis‐targeted therapeutic strategies in Parkinson's disease
Jankovic, J. J. (2018) · Movement Disorders · doi:10.1002/mds.27534 · Cited by 47
Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease
Magnusen, A. F., Hatton, S. L., Rani, R., & Pandey, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.636139 · Cited by 47
Domínguez-Fernández, C., Egiguren-Ortiz, J., Razquin, J., Gómez-Galán, M., Heras-García, L. D. L., Paredes-Rodriguez, E., Astigarraga, E., Miguélez, C., & Barreda‐Gómez, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043321 · Cited by 52
Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”
Outeiro, T. F., Alcalay, R. N., Antonini, A., Attems, J., Bonifati, V., Cardoso, F., Chesselet, M., Hardy, J., Madeo, G., McKeith, I. G., et al. (2023) · Movement Disorders · doi:10.1002/mds.29419 · Cited by 47
Self-citationCellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
Jamebozorgi, K., Taghizadeh, E., Rostami, D., Pormasoumi, H., Barreto, G. E., Hayat, S. M. G., & Sahebkar, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1419-8 · Cited by 46
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders
Golde, T. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.027 · Cited by 45
Innate and adaptive immune abnormalities underlying autoimmune diseases: the genetic connections
Chi, X., Huang, M., Tu, H., Zhang, B., Lin, X., Xu, H., Dong, C., & Hu, X. (2023) · Science China Life Sciences · doi:10.1007/s11427-021-2187-3 · Cited by 47
Multi-omic insights into Parkinson's Disease: From genetic associations to functional mechanisms
Schilder, B. M., Navarro, E., & Raj, T. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105580 · Cited by 45
TRIM31 facilitates K27-linked polyubiquitination of SYK to regulate antifungal immunity
Wang, X., Zhang, H., Shao, Z., Zhuang, W., Sui, C., Liu, F., Chen, X., Hou, J., Kong, L., Liu, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00711-3 · Cited by 40
Trade-offs in aging lung diseases
van Moorsel, C. H. M. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000476 · Cited by 40
Fine-mapping of Parkinson’s disease susceptibility loci identifies putative causal variants
Schilder, B. M., & Raj, T. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab294 · Cited by 38
Freuer, D., & Meisinger, C. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00318-7 · Cited by 39
Extracellular alpha-synuclein: Sensors, receptors, and responses
Domingues, R., Sant’Anna, R., da Fonseca, A. C. C., Robbs, B. K., Foguel, D., & Outeiro, T. F. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105696 · Cited by 38
Cui, G., Li, S., Ye, H., Yang, Y., Huang, Q., Chu, Y., Shi, Z., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956005 · Cited by 40
Escherichia coli triggers α-synuclein pathology in the LRRK2 transgenic mouse model of PD
Liang, D., Liu, H., Jin, R., Feng, R., Wang, J., Qin, C., Zhang, R., Chen, Y., Zhang, J., Teng, J., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2276296 · Cited by 38
Lerche, S., Zimmermann, M., Wurster, I., Röeben, B., Fries, F. L., Deuschle, C., Waniek, K., Lachmann, I., Gasser, T., Jakobi, M., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.834580 · Cited by 37
Self-citationRheumatoid Arthritis and Risk of Parkinson Disease in Korea
Kang, J., Eun, Y., Jang, W., Cho, M. H., Han, K., Jung, J., Kim, Y., Kim, G.-T., Shin, D. W., & Kim, H. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0932 · Cited by 35
Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson’s Disease?
Rajamani, K. T., Li, P., Galvis, M. L. E., Labrie, V., Brundin, P., & Brundin, L. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171240 · Cited by 36
Li, M., Wan, J., Xu, Z., & Tang, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1103053 · Cited by 33
Iba, M., Kim, C., Florio, J. B., Mante, M., Adame, A., Rockenstein, E. M., Kwon, S., Rissman, R. A., & Masliah, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00286 · Cited by 33
RetractedGrathwohl, S. A., Quansah, E., Maroof, N., Steiner, J. A., Spycher, L., Benmansour, F., Durán-Pacheco, G., Siebourg‐Polster, J., Oroszlan‐Szovik, K., Remy, H., et al. (2021) · Free Neuropathology · doi:10.17879/freeneuropathology-2021-3326 · Cited by 32
Drug repurposing strategies of relevance for Parkinson’s disease
Fletcher, E. J. R., Kaminski, T. W., Williams, G. H., & Duty, S. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.841 · Cited by 31
Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy
Lai, T. T., Kim, Y. J., Ma, H.-I., & Kim, Y. E. (2022) · Journal of Movement Disorders · doi:10.14802/jmd.21078 · Cited by 32
Unraveling Risk Genes of COVID-19 by Multi-Omics Integrative Analyses
Baranova, A. V., Cao, H., & Zhang, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.738687 · Cited by 35
Brain-gut-microbiota axis in Parkinson’s disease: A historical review and future perspective
Dong, S., Sun, M., He, C. H., & Cheng, H. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.015 · Cited by 32
Genetic overlap between Parkinson’s disease and inflammatory bowel disease
Kang, X., Ploner, A., Wang, Y., Ludvigsson, J. F., Williams, D. M., Pedersen, N. L., & Wirdefeldt, K. (2022) · Brain Communications · doi:10.1093/braincomms/fcad002 · Cited by 32
Self-citationBoles, J. S., Krueger, M. E., Jernigan, J. E., Cole, C. L., Neighbarger, N. K., Huarte, O. U., & Tansey, M. G. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.02.007 · Cited by 31
Cheng, W., Zhu, Q., & Zhang, H. (2020) · Genes · doi:10.3390/genes11091100 · Cited by 31
Induced pluripotent stem cell‐based modeling of mutant LRRK 2‐associated Parkinson's disease
Weykopf, B., Haupt, S., Jungverdorben, J., Flitsch, L. J., Hebisch, M., Liu, G., Suzuki, K., Belmonte, J. C. I., Peitz, M., Blaess, S., et al. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14345 · Cited by 30
Gut–Brain Axis: Potential Factors Involved in the Pathogenesis of Parkinson's Disease
Chao, Y., Gulam, M. Y., Chia, N. S. J., Feng, L., Rötzschke, O., & Tan, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00849 · Cited by 32
Metadata
- Authors
- Witoelar, A., Jansen, I. E., Wang, Y., Desikan, R. S., Gibbs, J. R., Blauwendraat, C., Thompson, W. K., Hernandez, D. G., Djurovic, S., Schork, A. J., Bettella, F., Ellinghaus, D., Franke, A., Lie, B. A., McEvoy, L. K., Karlsen, T. H., Lesage, S., Morris, H. R., Brice, A., Wood, N. W., Heutink, P., Hardy, J., Singleton, A. B., Dale, A. M., Gasser, T., Andreassen, O. A., Sharma, M., & for the International Parkinson’s Disease Genomics Consortium (IPDGC), N. A. B. E. C. (.
- Affiliations
- Oslo University Hospital (NO)
- German Center for Neurodegenerative Diseases (DE)
- University of Oslo (NO)
- University of California, San Francisco (US)
- National Institutes of Health (US)
- University of Copenhagen (DK)
- University of California San Diego (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Institute of Clinical Molecular Biology, Christian Albrechts University of Kiel, Kiel, Germany
- Centre National de la Recherche Scientifique (FR)
- National Hospital for Neurology and Neurosurgery (GB)
- UCL Queen Square Institute of Neurology (GB)
- University College London (GB)
- Hertie Institute for Clinical Brain Research (DE)
- Corresponding author
- Sharma, Manu
- ORCID
- Witoelar, Aree
- Jansen, Iris E.
- Wang, Yunpeng
- Desikan, Rahul S.
- Gibbs, J. Raphael
- Blauwendraat, Cornelis
- Thompson, Wesley K.
- Hernandez, Dena G.
- Djurovic, Srdjan
- Schork, Andrew J.
- Bettella, Francesco
- Ellinghaus, David
- Lie, Benedicte A.
- McEvoy, Linda K.
- Karlsen, Tom H.
- Lesage, Suzanne
- Morris, Huw R.
- Brice, Alexis
- Wood, Nicholas W.
- Heutink, Peter
- Hardy, John
- Singleton, Andrew B.
- Dale, Anders M.
- Gasser, Thomas
- Andreassen, Ole A.
- Sharma, Manu
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-07-01
- Volume
- 74
- Issue
- 7
- Pages
- 780
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC5710535
- OpenAlex
- W2622719965
- Semantic Scholar
- 77f8aa61d1d32875fc37fcce3fe356cd20cd596e
- Cited by
- 352
- References
- 84
- Citations by year
- 2026: 14 · 2025: 39 · 2024: 60 · 2023: 41 · 2022: 39 · 2021: 62 · 2020: 34 · 2019: 30 · 2018: 24 · 2017: 7
- FWCI
- 18.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Site cant be reached (submittedVersion)
- DZNE Pub (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Explore Bristol Research (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Biogen
- Washington University in St. Louis
- Johns Hopkins University
- University of Rochester
- Wellcome Trust
- Sandwell and West Birmingham Hospitals NHS Trust
- University Hospitals Birmingham NHS Foundation Trust
- Université de Lille
- Parkinson's UK (G-0907, J-0901, J-1402, K-1501)
- Imperial College London
- University College London
- University of Oxford
- Newcastle University
- Cardiff University
- University of Aberdeen
- Institut National de la Santé et de la Recherche Médicale
- Universiteit Leiden
- Universiteit van Amsterdam
- Radboud Universiteit
- Vrije Universiteit Amsterdam
- Eberhard Karls Universität Tübingen
- Centre National de la Recherche Scientifique
- Leids Universitair Medisch Centrum
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- Université Pierre et Marie Curie
- National Institutes of Health
- Genentech
- Medical Research Council
- Erasmus Universitair Medisch Centrum Rotterdam
- Helmholtz Zentrum München
- National Human Genome Research Institute
- National Institute of General Medical Sciences (R01GM104400)
- National Institute of Neurological Disorders and Stroke
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- Parkinson's disease, autoimmune disease, pleiotropy, type 1 diabetes, Crohn's disease, ulcerative colitis, rheumatoid arthritis, celiac disease, psoriasis, multiple sclerosis, LRRK2, HLA, MAPT, SETD1A, protein-protein interaction network, DNA methylation, gene expression, anti-inflammatory therapy
- MeSH terms
- Arthritis, Rheumatoid, Autoimmune Diseases, Celiac Disease, Colitis, Ulcerative, Crohn Disease, Diabetes Mellitus, Type 1, Humans, Multiple Sclerosis, Parkinson Disease, Psoriasis, Risk Factors, Genetic Predisposition to Disease, Genome-Wide Association Study, Genetic Loci, Genetic Pleiotropy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
